For research use only. Not for therapeutic Use.
V-0219 (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 can be used for obesity-associated diabetes research[1].
| Catalog Number | I043718 |
| CAS Number | 878453-71-5 |
| Synonyms | 4-[[1-[[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]piperidin-3-yl]methyl]morpholine |
| Molecular Formula | C20H25F3N4O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H25F3N4O2/c21-20(22,23)17-5-3-16(4-6-17)19-24-18(29-25-19)14-27-7-1-2-15(13-27)12-26-8-10-28-11-9-26/h3-6,15H,1-2,7-14H2 |
| InChIKey | VFQGZIAZHIRPPQ-UHFFFAOYSA-N |
| SMILES | C1CC(CN(C1)CC2=NC(=NO2)C3=CC=C(C=C3)C(F)(F)F)CN4CCOCC4 |
| Reference | [1]. Decara JM, et al. Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for “Diabesity”. J Med Chem. 2022 Apr 14;65(7):5449-5461. |
